XtalPi Nominates Its First siRNA Preclinical Candidate for IgA Nephropathy Nine Months After Program Initiation

CAMBRIDGE, Mass. and BEIJING, Oct. 15, 2026 — XtalPi Holdings Limited (“XtalPi,” HKEX: 2228), an AI- and robotics-driven drug and materials discovery company, today announced the nomination of its first internally developed small interfering RNA (siRNA) preclinical candidate (PCC) for the treatment of immunoglobulin A nephropathy (IgAN).